The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
about
Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase LevelsReview article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.Treating hepatitis C in the prison population is cost-saving.Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.Fibrosis progression in HCV carriers with mild hepatitis who possess the high-repetition variant of the DRD4 gene, a genetic marker for binge-drinking and risk-seeking behavior: a longitudinal study.
P2860
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The economics of treating chro ...... ently normal aminotransferase.
@en
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a
@nl
type
label
The economics of treating chro ...... ently normal aminotransferase.
@en
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a
@nl
prefLabel
The economics of treating chro ...... ently normal aminotransferase.
@en
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a
@nl
P2093
P2860
P1476
The economics of treating chro ...... tently normal aminotransferase
@en
P2093
P2860
P304
P356
10.1111/J.1365-2893.2005.00700.X
P577
2006-06-01T00:00:00Z